Dendrimer-based multilayer nanocarrier for potential synergistic paclitaxel–doxorubicin combination drug delivery

Doxorubicin-Loaded Silk Fibroin Nanospheres

“…已有研究显示, 在淋巴化疗中, 若采用腹腔注 射方式给药, 较大尺寸(几百纳米至几微米)的脂质体和 PLGA 微球载体相比于对应的小尺寸(小于 200 nm)微球 有更好的淋巴结靶向性能 [12～14] . 本研究选择的抗癌药物是阿霉素, 它是一种广谱的 抗癌药物, 对多种肿瘤均有作用, 其作用机理是嵌入 DNA 而抑制核酸的合成 [15,16] . 与大多数抗癌药物一样, 阿霉素也具有较强的毒副作用, 特别是具有较为明显的 心脏毒性 [17] , 因此为了降低其毒副作用, 有不少对于阿 霉素负载体系的研究报道, 例如采用表面包覆了聚合物 的氧化铁通过 pH 敏感的化学键连接阿霉素分子 [18] , 或 采用白蛋白纳米颗粒通过化学键连接阿霉素 [19] , 或采 用壳聚糖通过亲疏水相互作用负载阿霉素 [20] , 或采用 碳纳米管通过疏水相互作用和π-π相互作用负载阿霉 素 [21] 等.…”

Polyamidoamine and polyglycerol; their linear, dendritic and linear–dendritic architectures as anticancer drug delivery systems

“…117 Amphiphilic PAMAM dendrimer with core-shell structure containing hydrophobic and 60 hydrophilic domains (PAMAM-PCL-PEG) have been synthesized and successfully used for dual drug delivery of DOX and PTX. 154 Delivery of anticancer drugs and gene simultaneously is also an effective way to destroy the cancerous cells. Duplex oligodeoxynucleotides was conjugated on the PAMAM dendrimer and then DOX was loaded on the resulting conjugate.…”

An ultrasensitive LC–MS/MS method with liquid phase extraction to determine paclitaxel in both cell culture medium and lysate promising quantification of drug nanocarriers release in vitro

“…Moreover, poor aqueous solubility and serious side effects associated with commercial preparation of PTx (Taxol ® ) triggered the development of alternative PTx formulations without cremophor. Different nanocarrier systems including nanoparticles, liposomes, micelles, bioconjugates and dendrimers have been employed to improve PTx solubility and eliminate undesired side effects [10][11][12][13][14][15]. It was reported that PTx, delivered in polyanhydrides, was released very slowly, and only 15% of 0.042 mg/mL of PTx was released in 77 days [16].…”

“…Numerous analytical methods using liquid phase extraction and solid phase extraction combined to the LC-MS/MS technique were developed for ultrasensitive quantifi- cation of PTx in biological samples such as cells, plasma, urine, feces or tissues [19][20][21][22][23][24][25][26][27][28][29][30]. Nevertheless, most of the published works use high-performance liquid chromatography or spectrophotometric UV-vis absorbance [11][12][13][14][15]17] and radio labeled [16] detection to determine the in vitro profile of PTx release from nanocarriers. This makes us thinking about to what extend LC-MS/MS reported methods were suitable to quantify PTx in biological medium such as complete cell culture medium supplemented with 10% of fetal bovine serum.…”

“…Since PTx release kinetic is time and medium composition depending, a highly sensitive quantification of drug at short time is required to validate the use of such nanocarriers for drug delivery in cancer therapy. Indeed, due to its high hydrophobicity, most of in vitro studies of PTx release from nanocarriers were performed in simulated physiological medium supplemented with surfactant Tween 80 [11][12][13][14][15][16][17][18]. Numerous analytical methods using liquid phase extraction and solid phase extraction combined to the LC-MS/MS technique were developed for ultrasensitive quantifi- cation of PTx in biological samples such as cells, plasma, urine, feces or tissues [19][20][21][22][23][24][25][26][27][28][29][30].…”